Opaleye Management Inc. Buys Aptose Biosciences Inc, Ocular Therapeutix Inc, Intra-Cellular Therapies Inc, Sells Cara Therapeutics Inc, ShockWave Medical Inc, NextCure Inc

• New Purchases: ACHN, AQST, KDMN, RYTM, MGNX, FENC,
• Added Positions: APTO, OCUL, ITCI, EDAP, FLXN, CCXI, FTSV, NLTX, TPTX, RDUS, CRNX, MGTA, CDXS, ATXI, EIDX, EPZM, BOLD, AMRN, QURE, BHVN, ACAD, STXS, ZYME, ODT,
• Reduced Positions: QTRX, BPMC, TGTX, DCPH, FGEN, PRTO,
• Sold Out: CARA, SWAV, NXTC, SBBP, CBAY, VRML, ASMB,

For the details of Opaleye Management Inc.'s stock buys and sells, go to https://www.gurufocus.com/guru/opaleye+management+inc./current-portfolio/portfolio

1. Epizyme Inc (EPZM) - 1,384,200 shares, 6.99% of the total portfolio. Shares added by 1.41%
2. Aptose Biosciences Inc (APTO) - 4,085,000 shares, 4.76% of the total portfolio. Shares added by 467.36%
3. Codexis Inc (CDXS) - 1,400,000 shares, 4.58% of the total portfolio. Shares added by 3.70%
4. Forty Seven Inc (FTSV) - 562,000 shares, 4.54% of the total portfolio. Shares added by 32.24%
5. Stereotaxis Inc (STXS) - 4,112,500 shares, 4.52% of the total portfolio. Shares added by 1.04%

Opaleye Management Inc. initiated holding in Achillion Pharmaceuticals Inc. The purchase prices were between $3.55 and $6.45, with an estimated average price of $5.83. The stock is now traded at around $6.76. The impact to a portfolio due to this purchase was 0.94%. The holding were 760,000 shares as of .

Opaleye Management Inc. initiated holding in Aquestive Therapeutics Inc. The purchase prices were between $3.06 and $8.78, with an estimated average price of $5.27. The stock is now traded at around $4.38. The impact to a portfolio due to this purchase was 0.88%. The holding were 738,500 shares as of .

Opaleye Management Inc. initiated holding in Kadmon Holdings Inc. The purchase prices were between $2.58 and $4.98, with an estimated average price of $3.71. The stock is now traded at around $4.52. The impact to a portfolio due to this purchase was 0.87%. The holding were 940,373 shares as of .

Opaleye Management Inc. initiated holding in Rhythm Pharmaceuticals Inc. The purchase prices were between $19.53 and $25.5, with an estimated average price of $22.27. The stock is now traded at around $17.87. The impact to a portfolio due to this purchase was 0.52%. The holding were 110,500 shares as of .

Opaleye Management Inc. initiated holding in Macrogenics Inc. The purchase prices were between $7.95 and $12.27, with an estimated average price of $9.88. The stock is now traded at around $10.16. The impact to a portfolio due to this purchase was 0.45%. The holding were 200,500 shares as of .

Opaleye Management Inc. initiated holding in Fennec Pharmaceuticals Inc. The purchase prices were between $4.25 and $6.49, with an estimated average price of $5.39. The stock is now traded at around $7.82. The impact to a portfolio due to this purchase was 0.02%. The holding were 12,000 shares as of .

Opaleye Management Inc. added to a holding in Aptose Biosciences Inc by 467.36%. The purchase prices were between $1.83 and $5.67, with an estimated average price of $2.95. The stock is now traded at around $8.26. The impact to a portfolio due to this purchase was 3.92%. The holding were 4,085,000 shares as of .

Opaleye Management Inc. added to a holding in Ocular Therapeutix Inc by 84.05%. The purchase prices were between $2.57 and $4.73, with an estimated average price of $3.51. The stock is now traded at around $5.19. The impact to a portfolio due to this purchase was 1.89%. The holding were 5,107,500 shares as of .

Opaleye Management Inc. added to a holding in Intra-Cellular Therapies Inc by 139.18%. The purchase prices were between $7.76 and $38.49, with an estimated average price of $12.45. The stock is now traded at around $22.84. The impact to a portfolio due to this purchase was 1.66%. The holding were 406,600 shares as of .

Opaleye Management Inc. added to a holding in Edap TMS SA by 495.00%. The purchase prices were between $4.3 and $5.38, with an estimated average price of $4.7. The stock is now traded at around $3.77. The impact to a portfolio due to this purchase was 1.35%. The holding were 1,785,000 shares as of .

Opaleye Management Inc. added to a holding in Flexion Therapeutics Inc by 295.71%. The purchase prices were between $12.88 and $20.95, with an estimated average price of $16.97. The stock is now traded at around $16.53. The impact to a portfolio due to this purchase was 1.32%. The holding were 415,500 shares as of .

Opaleye Management Inc. added to a holding in ChemoCentryx Inc by 80.80%. The purchase prices were between $6.89 and $39.55, with an estimated average price of $18.21. The stock is now traded at around $48.00. The impact to a portfolio due to this purchase was 1.27%. The holding were 361,600 shares as of .

Opaleye Management Inc. sold out a holding in Cara Therapeutics Inc. The sale prices were between $16.11 and $25.98, with an estimated average price of $19.58.

Opaleye Management Inc. sold out a holding in ShockWave Medical Inc. The sale prices were between $29.4 and $44.98, with an estimated average price of $37.19.

Opaleye Management Inc. sold out a holding in NextCure Inc. The sale prices were between $25 and $92.22, with an estimated average price of $42.28.

Opaleye Management Inc. sold out a holding in Strongbridge Biopharma PLC. The sale prices were between $1.47 and $2.42, with an estimated average price of $1.91.

Opaleye Management Inc. sold out a holding in CymaBay Therapeutics Inc. The sale prices were between $1.33 and $5.93, with an estimated average price of $3.68.

Opaleye Management Inc. sold out a holding in Vermillion Inc. The sale prices were between $0.38 and $0.95, with an estimated average price of $0.67.